2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME)

Journal of Sexual Medicine

Volumn 6, Issue 7, 2009, Pages 1794-1808

  Shindel, Alan W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Daily dosing; Erectile dysfunction; Lower urinary tract symptoms; Penile rehabilitation; Phosphodiesterase type 5 inhibitors; Stuttering priapism

Indexed keywords

3 NITROTYROSINE; 8 ISOPROSTANE; ALFUZOSIN; CATALASE; CYCLIC GMP; DOXAZOSIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; FLUTAMIDE; GLUTATHIONE PEROXIDASE; INTERLEUKIN 8; LOSARTAN; NORADRENALIN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; SK 3530; SUPEROXIDE DISMUTASE; TACROLIMUS; TADALAFIL; TAMSULOSIN; UDENAFIL; UNCLASSIFIED DRUG; VARDENAFIL; IMIDAZOLE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE; TRIAZINE DERIVATIVE; VASODILATOR AGENT;

ADJUVANT THERAPY; ANTIOXIDANT ACTIVITY; ARTICLE; BLADDER CONTRACTION; BLADDER NECK STENOSIS; CAVERNOUS NERVE INJUR Y; CAVERNOUS NERVE INJURY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; EVENING DOSAGE; HEADACHE; HEART VENTRICLE HYPERTROPHY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; INTESTINE INJURY; LOW DRUG DOSE; LOWER URINARY TRACT SYMPTOM; LUNG DISEASE; MEAN ARTERIAL PRESSURE; MEMORY DISORDER; MONOTHERAPY; NEUROLOGIC DISEASE; NONHUMAN; PENILE VASCULAR DAMAGE; PENIS DISEASE; PENIS ERECTION; PENIS INJURY; PENIS NOCTURNAL TUMESCENCE; PRIAPISM; PRIORITY JOURNAL; PROSTATECTOMY; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RECURRENT DISEASE; SINGLE DRUG DOSE; SMOKING; SMOOTH MUSCLE RELAXATION; URINE FLOW RATE; DRUG EFFECTS; IMPOTENCE, VASCULOGENIC; MALE; PENIS; SECONDARY PREVENTION; UROLOGIC DISEASES; VASCULARIZATION;

HUMANS; IMIDAZOLES; IMPOTENCE, VASCULOGENIC; MALE; PENIS; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PRIAPISM; PROSTATECTOMY; PURINES; SECONDARY PREVENTION; SULFONES; TRIAZINES; UROLOGIC DISEASES; VASODILATOR AGENTS;

EID: 67649887476     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01347.x     Document Type: Article

References (53)

1. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral Sildenafil in the treatment of erectile dysfunction. Sildenafil study group. N Engl J Med 1998;338:1397-404.
2. Bella AJ, DeYoung LX, Al-Numi M, Brock GB. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Eur Urol 2007;52:990-1005.
3. Rambhatla A, Kovanecz I, Ferrini M, Gonzalez-Cadavid NF, Rajfer J. Rationale for phosphodiesterase 5 inhibitor use post-radical prostatectomy: Experimental and clinical review. Int J Impot Res 2008;20:30-4.
4. Hatzimouratidis K, Burnett AL, Hatzichristou S, McCullough AR, Montorsi F, Mulhall JP. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: A critical analysis of the basic science rationale and clinical application. Eur Urol 2009;55:334-47.
5. Bivalacqua TJ, Sussan TE, Gebska MA, Strong TD, Berkowitz DE, Biswal S, Burnett AL, Champion HC. Sildenafil inhibits superoxide formation and prevents endothelial dysfunction in a mouse model of secondhand smoke induced erectile dysfunction. J Urol 2009;181:899-906.
6. Kovanecz I, Rambhatla A, Ferrini M, Vernet D, Sanchez S, Rajfer J, Gonalez-Cadavid N. Long-term continuous sildenafil treatment ameliorates corporal venocclusive dysfunction (CVOD) induced by cavernosal nerve resection in rats. Int J Impot Res 2008;20:202-12.
7. Kovanecz I, Rambhatla A, Ferrini MG, Vernet D, Sanchez S, Rajfer J, Gonalez-Cadavid N. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int 2007;101:203-10.
8. Ferrini MG, Davila HH, Kovanecz I, Sanchez SP, Gonzalez-Cadavid NF, Rajfer J. Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology 2006;68:429-35.
9. Mulhall JP, Muller A, Donohue JF, Mullerad M. Kobylarz K, Paduch DA, Tal R, Li PS, Cohen-Gould L, Scardino PT. The functional and structural consequences of cavernous nerve injury are ameliorated by sildenafil citrate. J Sex Med 2008;5:1126-36.
10. Lagoda G, Jin L, Lehrfeld TJ, Liu T, Burnett AL. FK506 and sildenafil promote erectile function recovery after cavernous nerve injury through antioxidative mechanisms. J Sex Med 2007;4:908-16.
11. Vignozzi L, Morelli A, Filippi S, Vannelli GB, Mungai S, Marini M, Boddi V, Forti G, Maggi M. Effect of sildenafil administration on penile hypoxia induced by cavernous neurotomy in the rat. Int J Impot Res 2008;20:60-7.
12. Park K, Ryu KS, Li WJ, Kim SW, Paick JS. Chronic treatment with a type 5 phosphodiesterase inhibitor suppresses apoptosis of corporal smooth muscle by potentiating Akt signaling in a rat model of diabetic erectile dysfunction. Eur Urol 2008;53:1282-9.
13. De Young LX, Domes T, Lim KB, Carson J, Brock GB. Endothelial rehabilitation: The impact of chronic PDE5 inhibitors on erectile function and protein alteration in cavernous tissue of diabetic rats. Eur Urol 2008;54:213-20.
14. Toblli JE, Cao G, Lombrana A, Rivero M. Functional and morphological improvement in erectile tissue of hypertensive rats by long-term combined therapy with phosphodiesterase type 5 inhibitor and losartan. J Sex Med 2007;4:1291-303.
15. Levine LA, Greenfield JM, Estrada CR. Erectile dysfunction following surgical correction of Peyronie's disease and a pilot study of the use of sildenafil citrate rehabilitation for postoperative erectile dysfunction. J Sex Med 2005;2:241-7.
16. Mulhall JP, Land S, Parker M, Waters WB, Flanigan RC. The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med 2005;2:532-42.
17. Bannowsky A, Schulze H, van der Horst C, Hautmann S, Junemann KP. Recovery of erectile function after nerve sparing radical prostatectomy: Improvement with nightly low dose sildenafil. BJU Int 2008;101:1279-83.
18. Padma-Nathan H, McCullough AR, Levine LA, Lipshultz LI, Siegel R, Montorsi F, Giuliano F, Brock G, Study Group. Randomized, double-blind, placebo-controlled study of post-operative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve sparing radical prostatectomy. Int J Impot Res 2008;20:479-86.
19. Montorsi F, Brock G, Lee J, Shapiro J, van Poppel H, Graefen M, Stief C. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008;54:924-31.
20. Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: A pilot study. Int J Impot Res 2007;19:200-7.
21. Natali A, Bartolini M, Lucarini S, Vignolini G, Nelli F, Menchi I. Statistical evaluation of hemodynamic effects of regular use of sildenafil on the human corpora cavernosa. Urol Int 2009;82:53-60.
22. Burnett AL, Strong TD, Trock BJ, Jin L, Bivalacqua TJ, Musicki B. Serum biomarker measurements of endothelial function and oxidative stress after daily dosing of sildenafil in type 2 diabetic men with erectile dysfunction. J Urol 2009;181:245-51.
23. Zumbe J, Porst H, Sommer F, Grohmann W, Beneke M, Ulbrich E. Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: Findings of the RESTORE study. Eur Urol 2008;54:204-12.
24. McCullough AR, Levine LA, Padma-Nathan H. Return of nocturnal erections and erectile function after bilateral nerve-sparing radical prostatectomy in men treated with nightly with sildenafil citrate: Sub-analysis of a longitudinal randomized double-blind placebo-controlled trial. J Sex Med 2008;5:476-84.
25. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med 2006;3:1077-84.
26. McVary KT, McKenna KE. The relationship between erectile dysfunction and lower urinary tract symptoms: Epidemiological, clinical, and basic science evidence. Curr Urol Rep 2004;5:251-7.
27. Wong P, Lawrentschuck N, Bolton DM. Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: The best of both worlds. Curr Opin Urol 2009;19:7-12.
28. Kedia GT, Uckert S, Jonas U, Kuczyk MA, Burchardt M. The nitric oxide pathway in the human prostate: Clinical implications in men with lower urinary tract symptoms. World J Urol 2008;26:603-9.
29. Oger S, Behr-Roussel D, Gorny D, Lecoz O, Lebret T, Denoux Y, Faix A, Leriche A, Wayman C, Alexandre L, Giuliano F. Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue. J Sex Med 2009;6:836-47.
30. Oger S, Behr-Roussel D, Gorny D, Tremeaux JC, Combes M, Alexandre L, Giuliano F. Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum. J Sex Med 2008;5:935-45.
31. Beamon CR, Mazar R, Salkini MW, Phull HS, Comiter CV. The effect of sildenafil citrate on bladder outlet obstruction: A mouse model. BJU Int 2008 [Epub ahead of print, Dec 19].
32. Matsumoto S, Hanai T, Uemura H, Levin RM. Effects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model. BJU Int 2008 [Epub ahead of print, Nov 13].
33. McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized, double-blind trial. J Urol 2007;177:1071-7.
34. Roehrborn CG, McVary KT, Elion-Mbousaa A, Viktrup L. Tadalafil administered once daily for Lower Urinary Tract Symptoms secondary to benign prostatic hyperplasia: A Dose Finding Study. J Urol 2008;180:1228-34.
35. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomized, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53:1236-44.
36. Liguori G, Trombetta C, De Giorgi G, Pomara G, Maio G, Vecchio D, Ocello G, Ollandini G, Bucci S, Belgrano E. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: An integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med 2009;6:544-52.
37. Bechara A, Romano S, Casabe A, Haime S, Dedola P, Hernandez C, Rey H. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadafil in the treatment of LUTS/BPH. Pilot Study. J Sex Med 2008;5:2170-8.
38. Chung BH, Lee JY, Lee SH, Yoo SJ, Lee SW, Oh CY. Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS. Int J Impot Res 2009;2:122-8.
39. Barry MJ, Williford WO, Chang Y, Machi M, Jones KM, Walker-Corkery E, Lepor H. Benign prostatic hyperplasia specific health status measures in clinical research: How much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995;154:1770-4.
40. Gales BJ, Gales MA. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men. Ann Pharmacother 2008;42:111-5.
41. Mostafa T. Oral phosphodiesterase type 5 inhibitors: Nonerectogenic beneficial uses. J Sex Med 2008;5:2502-18.
42. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Grimminger F, Kurzyna M, Simonneau G; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57.
43. Wang T, Liu Y, Chen L, Wang X, Hu XR, Feng YL, Liu DS, Xu D, Duan YP, Lin J, Ou XM, Wen FQ. Effect of sildenafil on acrolein-induced airway inflammation and mucus production in rats. Eur Respir J 2009 [Epub ahead of print, Jan 7].
44. Ergin S, Gunduz B, Ugurlu H, Sivrioglu K, Oncel S, Gok S, Erhan B, Levendoglu F, Senocak O. A placebo-controlled, multicenter, randomized, double-blind, flexible-dose, two-way crossover study to evaluate the efficacy and safety of sildenafil in men with traumatic spinal cord injury and erectile dysfunction. J Spinal Cord Med 2008;31:522-31.
45. Safarinejad MR. Evaluation of the safety and efficacy of sildenafil citrate for erectile dysfunction in men with multiple sclerosis: A double-blind, placebo controlled, randomized study. J Urol 2009;181:252-8.
46. Farooq MU, Naravetla B, Moore PW, Majid A, Gupta R, Kassab MY. Role of sildenafil in neurological disorders. Clin Neuropharmacol 2008;31:353-62.
47. Ko IG, Shin MS, Kim BY, Kim SE, Sung YH, Kim TS, Shin MC, Cho HJ, Kim SC, Kim SH, Kim KH, Shin DH, Kim CJ. Tadalafil improves short term memory by suppressing ischemia-induced apoptosis of hippocampal neuronal cells in gerbils. Pharmacol Biochem Behav 2008; doi:10.1016/ j.pbb.2008.10.009.
48. Vlachopoulos C, Ioakeimidis N, Rokkas K, Stefanadis C. Cardiovascular effects of phosphodiesterase type 5 inhibitors. J Sex Med 2008 [Epub ahead of print, Dec 2].
49. Movsesian M, Stehlik J, Vandeput F, Bristow MR. Phosphodiesterase inhibition in heart failure. Heart Fail Rev 2008 [Epub ahead of print, Dec 19].
50. Perk H, Armagan A, Naziroǧlu M, Soyupek S, Hoscan MB, Sütcü R, Ozorak A, Delibas N. Sildenafil citrate as a phosphodiesterase inhibitor has an antioxidant effect in the blood of men. J Clin Pharm Ther 2008;33:635-40.
51. De LaVega AJ, Derk CT. Phosphodisesterase-5 inhibitors for the treatment of Raynaud's: A novel indication. Expert Opin Investig Drugs 2009;18:23-9.
52. Kato N, Mashita Y, Kato S, Mitsufuji S, Yoshikawa T, Takeuchi K. Sildenafil, an inhibitor of phosphodiesterase subtype 5, prevents indomethacin-induced small-intestinal ulceration in rats via a NO/ cGMP-dependent mechanism. Dig Dis Sci 2008 [Epub ahead of print, Dec 20].
53. Niko J. Kallianiotis. New Suspect in sports doping is, no joke, Viagra. New York Times Online, November 11, 2008. Available at: http://www.nytimes.com/2008/11/23/sports/23viagra.html (accessed January 2, 2009).